Investigator to Congress: Ketek data was known to be fraudulent

Share this article:

A subpoenaed FDA criminal investigator has told Congress that Aventis should have known that data it submitted to support the approval of antibiotic Ketek was fraudulent. Agent Douglas Loveland testified that there were so many “red flags” in one study that the company should have notified the FDA. 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions